Celldex Therapeutics Inc (CLDX)
22.26
+0.35
(+1.60%)
USD |
NASDAQ |
Feb 12, 16:00
22.26
0.00 (0.00%)
After-Hours: 20:00
Key Stats
Price and Performance | |
---|---|
Market Cap | 1.477B |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
All-Time High (Daily) | Upgrade |
Year to Date Total Returns (Daily) | Upgrade |
1 Month Total Returns (Daily) | Upgrade |
1 Year Total Returns (Daily) | -40.78% |
Valuation | |
PE Ratio | -- |
PE Ratio (Forward) | Upgrade |
PS Ratio | 135.69 |
Price to Book Value | 1.879 |
EV to EBITDA | Upgrade |
Dividend | |
---|---|
Dividend | -- |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | 0.00 |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | 99.67% |
Profile
Edit
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140,CDX-0159/Anti-KIT Program, and CDX-527. |
URL | https://www.celldex.com |
Investor Relations URL | https://ir.celldex.com |
HQ State/Province | New Jersey |
Sector | Health Care |
Industry | Biotechnology |
Next Earnings Release | Feb. 26, 2025 (est.) |
Last Earnings Release | Oct. 28, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |
Ratings
Profile
Edit
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140,CDX-0159/Anti-KIT Program, and CDX-527. |
URL | https://www.celldex.com |
Investor Relations URL | https://ir.celldex.com |
HQ State/Province | New Jersey |
Sector | Health Care |
Industry | Biotechnology |
Next Earnings Release | Feb. 26, 2025 (est.) |
Last Earnings Release | Oct. 28, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |